AXSM Axsome Therapeutics
- 83.845
- -0.935-1.10%
Axsome Therapeutics News
Axsome Therapeutics Mixed Alzheimer's Disease Agitation Data Disappoints but Approvability Seen Likely, Mizuho Says
Leerink Partners Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $110
Cantor Fitzgerald Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $124
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $116 to $180
Axsome Therapeutics Price Target Raised to $124 From $121 at Cantor Fitzgerald
Truist Says 'Aggressive' Buying Axsome Therapeutics After AXS-05 ADA Data
Express News | HC Wainwright & Co. Reiterates Buy on Axsome Therapeuticsto Buy
Axsome Therapeutics (AXSM) Gets a Buy From Mizuho Securities
Buy Rating for Axsome Therapeutics: Promising AXS-05 Efficacy in Alzheimer's Agitation
RBC Capital Adjusts Price Target on Axsome Therapeutics to $138 From $132, Keeps Outperform Rating
Express News | Axsome Therapeutics Inc : Needham Raises Target Price to $133 From $130
Positive Outlook for Axsome Therapeutics: AXS-05 Advances Despite Setbacks
Axsome Therapeutics Stock Slips 12% On Mixed Results On Alzheimer's Study
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday
Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts
Analysts' Opinions Are Mixed on These Healthcare Stocks: Axsome Therapeutics (AXSM) and Ascendis Pharma (ASND)
Express News | Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target
Axsome's Drug Candidate for Alzheimer's Disease Agitation Meets Primary Endpoint in Phase 3 Trial, Falls Short in Another
No Data